Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

January 24, 2017
Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In an announcement on Jan. 3, the Shanghai-based immunotherapy and stem cell therapy company said it was expanding cell production in China to enable production of personalized CAR-T treatments in China for 10,000 patients annually. The company is focusing on becoming a leader in the area in China, but is manufacturing therapies according to both Chinese and US standards, Liu said in an interview at Biotech Showcase.
Previous Article
It’s all happening at Biotech Showcase™ Week
It’s all happening at Biotech Showcase™ Week

Guest post by Constantine Theodoropulos, President, GO Therapeutics Thankfully there is a holiday between n...

Next Article
Lifetime trends in biopharmaceutical innovation: Recent evidence and implications
Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life...